Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

NCT05058404 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

605

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
DRUG: Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)
DRUG: Immunochemotherapy regimen: R-CHOP (Arm A)
DRUG: Immunochemotherapy regimen: R-CHOP (Arm B)
DRUG: Immunochemotherapy regimen: G-bendamustine (Arm A)
DRUG: Immunochemotherapy regimen: G-bendamustine (Arm B)
DRUG: Immunochemotherapy regimen: G-CHOP (Arm A)
DRUG: Immunochemotherapy regimen: G-CHOP (Arm B)
DRUG: Immunochemotherapy regimen: G-CVP (Arm A)
DRUG: Immunochemotherapy regimen: G-CVP (Arm B)

Sponsor

Fondazione Italiana Linfomi - ETS